Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lintuzumab Ac 225 - Actinium Pharmaceuticals

Next Previous
Drug Profile

Lintuzumab Ac 225 - Actinium Pharmaceuticals

Alternative Names: 225Ac-HuM-195; 225Ac-lintuzumab; Ac-225-Lintuzumab; AC225 MOAB M195; Ac225 monoclonal antibody M195; Actimab-A; Actimab-M; Actimab-MDS; Actinium-225 (225Ac)-Lintuzumab; Actinium-225-labelled HuM195; HuM195-Ac-225

Latest Information Update: 10 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDL BioPharma
  • Developer Actinium Pharmaceuticals; Baylor Research Institute; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Preclinical Solid tumours
  • No development reported Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 25 Apr 2025 Pharmacodynamic data from a preclinical trial in Acute myeloid leukemia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 28 Mar 2025 National Cancer Institute plans a phase-I trial for Myelodysplastic Syndrome (Second-line therapy or greater) in May 2025 (IV), (NCT06888323)
  • 20 Mar 2025 Actinium Pharmaceuticals and Memorial Sloan Kettering Cancer Center agree to co-develop and support clinical expansion of lintuzumab Ac 225's backbone therapy strategy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top